PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 2514595-0 1989 Effects of sulfonamides on a metabolite-regulated ATPi-sensitive K+ channel in rat pancreatic B-cells. Sulfonamides 11-23 ATP synthase inhibitory factor subunit 1 Rattus norvegicus 50-54 2557928-0 1989 Inhibitory effects of newly synthesized sulfonamide derivatives on calmodulin-dependent phosphodiesterase activity and their modulation of the external ATP-dependent permeability change in mammalian cultured cells. Sulfonamides 40-51 calmodulin 1 Homo sapiens 67-77 2557928-3 1989 We have synthesized several new sulfonamide derivatives, which were found to inhibit calmodulin-dependent phosphodiesterase. Sulfonamides 32-43 calmodulin 1 Homo sapiens 85-95 2616252-0 1989 Circular dichroic investigations into binding of sulfonamides to serum albumin. Sulfonamides 49-61 albumin Homo sapiens 65-78 2514595-1 1989 Intracellular ATP (ATPi)-sensitive K+ [K+(ATP)] channels are now a recognized site of action of clinically useful hypoglycemic and hyperglycemic sulfonamides. Sulfonamides 145-157 ATP synthase inhibitory factor subunit 1 Rattus norvegicus 19-23 2496258-11 1989 Kinetically the enzyme was similar to CA II with respect to hydrase and esterase activities and to inhibition by various sulfonamides. Sulfonamides 121-133 carbonic anhydrase 2 Homo sapiens 38-43 2692515-3 1989 A beta-lactamase with an isoelectric point (pI) of 5.9 was detected in strain CB-134, and the corresponding gene was transferred by conjugation to E. coli together with the associated aminoglycoside resistance determinant [AAC(3)-II] and tetracycline, trimethoprim, and sulfonamide resistance. Sulfonamides 270-281 aminoglycoside N(3')-acetyltransferase III Escherichia coli 223-232 2734988-8 1989 Within the last decades when sulfonamides, antibiotics and insulin were discovered and produced the mortality ratio decreased. Sulfonamides 29-41 insulin Homo sapiens 59-66 3237218-3 1988 Inhibition experiments with a number of sulfonamides to determine the fine structural specificities of the sulfamethoxazole reactive IgE antibodies in three patients revealed that sulfamethoxazole and, depending on the serum, sulfamerazine and sulfamethizole, were the most potent inhibitors of IgE binding, whereas the parent sulfonamide, sulfanilamide, was a very poor inhibitor. Sulfonamides 40-51 immunoglobulin heavy constant epsilon Homo sapiens 133-136 2656382-2 1989 The beta-lactamase gene was carried on a plasmid (pUK734) along with resistance determinants to sulphonamides and tetracycline. Sulfonamides 96-109 beta-lactamase Escherichia coli 4-18 3237218-3 1988 Inhibition experiments with a number of sulfonamides to determine the fine structural specificities of the sulfamethoxazole reactive IgE antibodies in three patients revealed that sulfamethoxazole and, depending on the serum, sulfamerazine and sulfamethizole, were the most potent inhibitors of IgE binding, whereas the parent sulfonamide, sulfanilamide, was a very poor inhibitor. Sulfonamides 40-52 immunoglobulin heavy constant epsilon Homo sapiens 133-136 3203057-15 1988 Although the competitive inhibition between some sulphonamides and tolbutamide is consistent with metabolism by the same isozyme of cytochrome P-450 it does not prove it and further studies with purified enzymes will be necessary to confirm this. Sulfonamides 49-62 cytochrome P450 family 4 subfamily F member 3 Homo sapiens 132-148 2427907-5 1986 A sulfonamide derivative, the compound N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W-7) (2.5 X 10(-5)-2 X 10(-4) M), which selectively binds to CaM, inhibited the release of histamine from basophils. Sulfonamides 2-13 calmodulin 1 Homo sapiens 166-169 3680198-1 1987 Calmodulin antagonists, including phenothiazine, sulfonamide, butyrophenone, and imidazolium derivatives, were in vitro inhibitors of pea mitochondrial pyruvate dehydrogenase complex activity. Sulfonamides 49-60 calmodulin 1 Homo sapiens 0-10 3579525-2 1987 An interaction model for the binding of sulfonamides on human serum albumin]. Sulfonamides 40-52 albumin Homo sapiens 68-75 2434548-0 1987 Studies of human IgE to a sulfonamide determinant. Sulfonamides 26-37 immunoglobulin heavy constant epsilon Homo sapiens 17-20 2434548-1 1987 We tested the hypothesis that patients who experience immediate hypersensitivity reactions to sulfonamides (SM) express IgE that can bind to a N4-sulfonamidoyl determinant (N4-SM). Sulfonamides 94-106 immunoglobulin heavy constant epsilon Homo sapiens 120-123 2434548-1 1987 We tested the hypothesis that patients who experience immediate hypersensitivity reactions to sulfonamides (SM) express IgE that can bind to a N4-sulfonamidoyl determinant (N4-SM). Sulfonamides 108-110 immunoglobulin heavy constant epsilon Homo sapiens 120-123 6765679-0 1981 Effect of bovine serum albumin on the absorption of sulfonamides in the rat. Sulfonamides 52-64 albumin Rattus norvegicus 17-30 6502522-7 1984 A sulfonamide derivative, W-7, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (10(-5)-2 X 10(-4) M), which selectively binds to CaM, inhibited the release of lysosomal enzymes from PMNs. Sulfonamides 2-13 calmodulin 1 Homo sapiens 146-149 6192958-2 1983 We have investigated the possibility that calmodulin plays a role in immediate hypersensitivity reactions by evaluating the effects of two agents, trifluoperazine dihydrochloride (TFP) and the sulfonamide derivative N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) which selectively bind to calmodulin. Sulfonamides 193-204 calmodulin 1 Homo sapiens 42-52 6120173-3 1981 Fc-mediated phagocytosis was also depressed by W-7, a sulfonamide derivative that inhibits the activity of Ca2+-calmodulin. Sulfonamides 54-65 calmodulin 1 Homo sapiens 112-122 3081459-16 1986 The isoenzyme CA III, which is resistant to inhibition by sulfonamides, did not appear to be present in these ocular tissues, since the histochemical staining of enzyme activity was completely abolished by 10(-6) M acetazolamide. Sulfonamides 58-70 carbonic anhydrase 3 Homo sapiens 14-20 3918940-2 1985 A decrease of the activities of C1, C2, C3, C5 and one or several of the components C6-9 was observed after treatment of normal human serum with the sulfonamide sulfisomidine. Sulfonamides 149-160 complement C6 Homo sapiens 84-88 6433417-8 1984 The carbonic anhydrase inhibitors methazolamide and benzolamide both yielded IC50 values of 10(-5) M. This pattern of inhibitory potency of the three sulfonamides is incompatible with their inhibitory effects on the two known cytosolic isoenzymes of skeletal muscle, CAII and CAIII. Sulfonamides 150-162 carbonic anhydrase 2 Oryctolagus cuniculus 267-271 6716242-0 1984 Structure-activity relationships of sulfonamide drugs and human carbonic anhydrase C: modeling of inhibitor molecules into the receptor site of the enzyme with an interactive computer graphics display. Sulfonamides 36-47 carbonic anhydrase 2 Homo sapiens 64-84 6716242-1 1984 We have analyzed the molecular interaction of 28 sulfonamide inhibitors with human carbonic anhydrase C (HCAC) using an interactive computer graphic display. Sulfonamides 49-60 carbonic anhydrase 2 Homo sapiens 83-103 6340631-3 1983 Insulin and glucose determinations during a 48-hour fast while the patient was rechallenged with this compound, as compared with those obtained during a 72-hour fast performed 12 days after discontinuation of the therapy, suggest that the hypoglycemic episode was related to hyperinsulinemia probably induced by the sulfonamide. Sulfonamides 316-327 insulin Homo sapiens 0-7 6253340-1 1980 Hypoglycaemic sulphonamides stimulate net uptake of 45Ca++ and insulin release in isolated pancreatic islets. Sulfonamides 14-27 insulin Homo sapiens 63-70 7235014-7 1981 These same sulfonamides also reduced glucose-6-phosphate dehydrogenase (G-6-PD) activity in mucosal cell homogenates. Sulfonamides 11-23 glucose-6-phosphate dehydrogenase Homo sapiens 37-70 7235014-7 1981 These same sulfonamides also reduced glucose-6-phosphate dehydrogenase (G-6-PD) activity in mucosal cell homogenates. Sulfonamides 11-23 glucose-6-phosphate dehydrogenase Homo sapiens 72-78 7016524-6 1981 Individuals with a genetic defect of this enzyme are extremely susceptible to hemolysis, when exposed to oxidant drugs (such as certain antimalarials and sulfonamides) because of the inability of their red cells to regenerate NADPH. Sulfonamides 154-166 2,4-dienoyl-CoA reductase 1 Homo sapiens 226-231 146819-2 1978 The sulfonamide (Su) and streptomycin/spectinomycin (Sm/Sp) resistance genes are located on EcoRI fragment G of NR1. Sulfonamides 17-19 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 112-115 482171-3 1979 A first, uncomplicated UTI should be treated with sulfonamides or nitrofurantoin. Sulfonamides 50-62 alpha-1-microglobulin/bikunin precursor Homo sapiens 23-26 581068-6 1978 The most common causative organism of UTI was Escherichia coli, and the isolates were usually sensitive to ampicillin, sulphonamides, trimethoprim, and nitrofurantoin. Sulfonamides 119-132 alpha-1-microglobulin/bikunin precursor Homo sapiens 38-41 666540-0 1978 [Reactions of N-alkoxycycliminium salts, VIII: reactions of N-methoxypyridinium salts with aromatic amines and sulfonamides. Sulfonamides 111-123 cytochrome c oxidase subunit 8A Homo sapiens 41-45 385600-0 1979 The characteristics and significance of sulfonamides as substrates for Escherichia coli dihydropteroate synthase. Sulfonamides 40-52 Dihydropteroate synthase Escherichia coli 88-112 729128-0 1978 Effect of salicylate on the binding of sulfonamides to bovine serum albumin. Sulfonamides 39-51 albumin Homo sapiens 62-75 146819-2 1978 The sulfonamide (Su) and streptomycin/spectinomycin (Sm/Sp) resistance genes are located on EcoRI fragment G of NR1. Sulfonamides 4-15 glutamate ionotropic receptor NMDA type subunit 1 Homo sapiens 112-115 945984-0 1976 Circular dichroism studies on the interaction of four structurally related long-acting sulfonamides with human and bovine serum albumin. Sulfonamides 87-99 albumin Homo sapiens 122-135 987187-2 1976 Effect of sulfonamides on the binding of warfarin with bovine serum albumin]. Sulfonamides 10-22 albumin Homo sapiens 68-75 4376950-1 1974 Sulphonamide adducts of three Co(II) carbonic anhydrases were investigated by e.p.r. Sulfonamides 0-12 mitochondrially encoded cytochrome c oxidase II Homo sapiens 30-36 945561-0 1976 Influence of some salicylates and sulfonamides on binding by albumin of SPC-703 and tolbutamide. Sulfonamides 34-46 proline rich protein gene cluster Homo sapiens 72-75 945561-4 1976 Binding of SPC-703 and tolbutamide was decreased mostly in the presence of sulfadimetoxine, but this sulfonamide increased the concentration of free tolbutamide more than that of SPC-703. Sulfonamides 101-112 proline rich protein gene cluster Homo sapiens 11-14 945561-4 1976 Binding of SPC-703 and tolbutamide was decreased mostly in the presence of sulfadimetoxine, but this sulfonamide increased the concentration of free tolbutamide more than that of SPC-703. Sulfonamides 101-112 proline rich protein gene cluster Homo sapiens 179-182 234739-3 1975 The seven resonances observed in the histidine region of the proton magnetic resonance (pmr) spectrum of human carbonic anhydrase B and reported in the preceding paper are studied in the presence of sulfonamide, azide, cyanide, and chloride inhibitors and in metal-free, cadmium substituted, cobalt substituted, and carboxymethylated forms of the enzyme. Sulfonamides 199-210 carbonic anhydrase 2 Homo sapiens 111-131 234740-3 1975 Resonances of the histidine region of human carbonic anhydrase B have been studied by proton magnetic resonance spectroscopy in the presence of seven sulfonamide inhibitors. Sulfonamides 150-161 carbonic anhydrase 2 Homo sapiens 44-64 4617937-2 1974 Treatment of falciparum malaria in the Gambia, with BRL 50216 (4,6-diamino-(3, 4-dichlorobenzyloxy)-1,2-dihydro-2 2-dimethyl-1,3,5-triazine hydrochloride) alone and in combination with sulphonamides,. Sulfonamides 185-198 bromodomain containing 1 Homo sapiens 52-55 4212119-0 1974 Kinetics of complex formation between human carbonic anhydrase B and heterocyclic sulfonamides. Sulfonamides 82-94 carbonic anhydrase 2 Homo sapiens 44-64 4204344-0 1974 Structure relationship for binding of sulfonamides and penicillins to bovine serum albumin by fluorescence probe technique. Sulfonamides 38-50 albumin Homo sapiens 77-90 6035101-0 1967 Effect of insulin on the metabolism of sulfonamides. Sulfonamides 39-51 insulin Homo sapiens 10-17 4108538-2 1971 Sulfonamides also inhibited (a) iodination of Candida cells by normal neutrophils; (b) candidacidal activity in cell-free systems containing purified human myeloperoxidase, hydrogen peroxide, and potassium iodide; and (c) accumulation of molecular iodine in analogously constructed cell-free systems. Sulfonamides 0-12 myeloperoxidase Homo sapiens 156-171 4108538-4 1971 Sulfonamides appear to influence the function of human neutrophils predominantly by interfering with myeloperoxidase-mediated pathways. Sulfonamides 0-12 myeloperoxidase Homo sapiens 101-116 4991543-0 1970 [Pharmacology and pharmacodynamics of a hypoglycemic sulfonamide very active on insulin secretion and the neogenesis of beta cells of pancreatic Langerhans islets]. Sulfonamides 53-64 insulin Homo sapiens 80-87 5658018-0 1968 Hemolytic effect of sulfonamides in patients with erythrocytes deficient in glucose-6-phosphate dehydrogenase. Sulfonamides 20-32 glucose-6-phosphate dehydrogenase Homo sapiens 76-109 4942542-0 1970 Dihydrofolate reductase inhibitors as antimicrobial agents and their potentiation by sulfonamides. Sulfonamides 85-97 dihydrofolate reductase Homo sapiens 0-23 5677621-2 1968 Binding of sulfonamides to bovine serum albumin. Sulfonamides 11-23 albumin Homo sapiens 34-47 4379842-0 1965 [Methemoglobin formation by sulfonamides in a system containing liver homogenates, erythrocytes, NADPH and oxygen]. Sulfonamides 28-40 hemoglobin subunit gamma 2 Homo sapiens 1-14 13708145-0 1961 [Action of a sulfonamide (3-sulfanilamido-6-methoxypyridazine) on the serum level of properdin]. Sulfonamides 13-24 complement factor properdin Homo sapiens 85-94 5842823-0 1965 On the mechanism of the binding of sulfonamides to bovine serum albumin. Sulfonamides 35-47 albumin Homo sapiens 58-71 14060511-0 1963 [ON THE PROBLEM OF METHEMOGLOBIN FORMATION CAUSED BY LONG-ACTING SULFONAMIDES]. Sulfonamides 65-77 hemoglobin subunit gamma 2 Homo sapiens 19-32 13867538-0 1962 [On the problem of the use of hypoglycemic sulfonamides in the treatment of patients with schizophrenia, resistant to insulin]. Sulfonamides 43-55 insulin Homo sapiens 118-125 13763657-0 1961 [Protective action of hypoglycemic sulfonamides against the diabetogenic effects of purified growth hormone]. Sulfonamides 35-47 growth hormone 1 Homo sapiens 93-107 13528592-0 1958 [Himsworth test & antidiabetic sulfonamides in insulin resistance]. Sulfonamides 35-47 insulin Homo sapiens 51-58 13647414-0 1959 [Muscle & hepatic glycogen changes induced by hypoglycemic sulfonamides appear to be due to stimulation of endogenous insulin secretion]. Sulfonamides 63-75 insulin Homo sapiens 122-129 13836343-0 1959 The hemolytic effect of various sulfonamides on subjects with a deficiency of glucose-6-phosphate dehydrogenase of erythrocytes. Sulfonamides 32-44 glucose-6-phosphate dehydrogenase Homo sapiens 78-111 13671070-0 1959 [Significance of insulin-inactivating properties of the liver (insulinase) in the mechanism of action of antidiabetic sulfonamides]. Sulfonamides 118-130 insulin degrading enzyme Homo sapiens 17-74 13579650-0 1957 [Synergistic action of sulfonamides & insulin in recently pancreatectomized dogs]. Sulfonamides 23-35 insulin Canis lupus familiaris 42-49 13491948-0 1957 [Insulin resistance reduced by antidiabetic sulfonamides during a persistent infected perforating illness]. Sulfonamides 44-56 insulin Homo sapiens 1-8 13560210-0 1958 [Insulinase and its inhibition by hypoglycemic sulfonamides; data on insulin sensitivity during tolbutamide therapy]. Sulfonamides 47-59 insulin degrading enzyme Homo sapiens 1-11 13311506-0 1956 Insulin-sparing sulfonamides. Sulfonamides 16-28 insulin Homo sapiens 0-7 13411728-0 1957 [Experiments in including hypoglycemic comas by a combination of insulin & the oral hypoglycemic sulfonamide BZ 55]. Sulfonamides 101-112 insulin Homo sapiens 65-72 13319476-0 1956 Insulin-sparing sulfonamides. Sulfonamides 16-28 insulin Homo sapiens 0-7 13437578-0 1956 [Potentiation by certain sulfonamides of hypoglycemic effects of insulin administered by digestive route; study in normal or depancreatized dogs]. Sulfonamides 25-37 insulin Canis lupus familiaris 65-72 13421047-0 1956 [Potentiation of the action of insulin by hypoglycemic sulfonamides]. Sulfonamides 55-67 insulin Homo sapiens 31-38 13414248-0 1956 [Reenforcement and prolongation of the effects of insulin by hypoglycemic and antidiabetic substances sulfonamides]. Sulfonamides 102-114 insulin Homo sapiens 50-57 13080044-0 1953 [The blood-CSF ratio of drug concentrations, based on studies of better known sulfonamides]. Sulfonamides 78-90 colony stimulating factor 2 Homo sapiens 11-14 13414255-0 1956 [Reenforcement of the effect of insulin with hypoglycemic sulfonamides]. Sulfonamides 58-70 insulin Homo sapiens 32-39 13296877-0 1956 The inhibition of insulinase by hypoglycemic sulfonamides. Sulfonamides 45-57 insulin degrading enzyme Homo sapiens 18-28 18909164-0 1948 The binding of some sulfonamides by bovine serum albumin. Sulfonamides 20-32 albumin Homo sapiens 43-56 14818800-0 1951 [Sulfonamide inhibition of serum lysozyme. Sulfonamides 1-12 lysozyme Homo sapiens 33-41 33978027-10 2021 As observed for stereoisomers of potent KOR agonists, phenylacetamide 35a and more importantly sulfonamides 33a and 33b show moderate affinity at sigma1 receptors (Ki = 109-208 nM). Sulfonamides 95-107 opioid receptor kappa 1 Homo sapiens 40-43 34052739-2 2021 Classical carbonic anhydrase (CA) inhibitors are based on sulfonamide groups, but inhibiting all CA isoforms nonspecifically, thereby causing undesired side effects, is the main drawback of these types of inhibitors. Sulfonamides 58-69 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 10-28 34052739-2 2021 Classical carbonic anhydrase (CA) inhibitors are based on sulfonamide groups, but inhibiting all CA isoforms nonspecifically, thereby causing undesired side effects, is the main drawback of these types of inhibitors. Sulfonamides 58-69 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 30-32 33829648-3 2021 Molecular docking studies of the hybrids with the essential bacterial enzyme DHPS showed complexes with low binding energies, suggesting that DHPS could be a possible target for the antibacterial sulfonamide-eugenol hybrids. Sulfonamides 196-207 deoxyhypusine synthase Homo sapiens 77-81 34023639-10 2021 Hence, we also evaluated six sulfonamide derivatives for off-target in-vitro bovine carbonic anhydrase-II inhibition. Sulfonamides 29-40 carbonic anhydrase 2 Bos taurus 84-105 33829648-3 2021 Molecular docking studies of the hybrids with the essential bacterial enzyme DHPS showed complexes with low binding energies, suggesting that DHPS could be a possible target for the antibacterial sulfonamide-eugenol hybrids. Sulfonamides 196-207 deoxyhypusine synthase Homo sapiens 142-146 33517002-0 2021 Synthesis of novel sulfonamide derivatives containing pyridin-3-ylmethyl 4-(benzoyl)piperazine-1-carbodithioate moiety as potent PKM2 activators. Sulfonamides 19-30 pyruvate kinase M1/2 Homo sapiens 129-133 33530019-4 2021 These sulfonamides showed good inhibition activity against isoforms hCA I, hCA II and hCA XIII. Sulfonamides 6-18 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 68-81 33511940-2 2021 Interestingly, there is emerging evidence that the sulfonamide-type COX-2 selective inhibitors (coxibs) demonstrate inhibitory action against the cancer-related hCA isoforms, confirmed by X-ray crystal structures for celecoxib and valdecoxib complexes with the hCA active site. Sulfonamides 51-62 HCA1 Homo sapiens 261-264 33530019-4 2021 These sulfonamides showed good inhibition activity against isoforms hCA I, hCA II and hCA XIII. Sulfonamides 6-18 carbonic anhydrase 13 Homo sapiens 86-94 33418063-0 2021 Discovery of Carbon-11 Labeled Sulfonamide Derivative: A PET Tracer for Imaging Brain NLRP3 Inflammasome. Sulfonamides 31-42 NLR family pyrin domain containing 3 Homo sapiens 86-91 33418063-2 2021 Our recent medicinal chemistry campaign on developing sulfonamide-based NLRP3 inhibitors led to an analog, 1, with a methoxy substituent amenable to labeling with carbon-11. Sulfonamides 54-65 NLR family pyrin domain containing 3 Homo sapiens 72-77 33316409-7 2021 Alternatively, introducing of sulfonamide fragment into C2-substituent of pyrrolo[2,3-d]pyrimidine provided the clue for future optimization to afford new CDK9 inhibitors. Sulfonamides 30-41 cyclin dependent kinase 9 Homo sapiens 155-159 33511940-3 2021 Consequently, the antineoplastic activity of the sulfonamide coxibs may be justified by the contribution of hCA inhibition to such processes in addition to COX-2 inhibition. Sulfonamides 49-60 HCA1 Homo sapiens 108-111 33511940-2 2021 Interestingly, there is emerging evidence that the sulfonamide-type COX-2 selective inhibitors (coxibs) demonstrate inhibitory action against the cancer-related hCA isoforms, confirmed by X-ray crystal structures for celecoxib and valdecoxib complexes with the hCA active site. Sulfonamides 51-62 prostaglandin-endoperoxide synthase 2 Homo sapiens 68-73 33511940-3 2021 Consequently, the antineoplastic activity of the sulfonamide coxibs may be justified by the contribution of hCA inhibition to such processes in addition to COX-2 inhibition. Sulfonamides 49-60 prostaglandin-endoperoxide synthase 2 Homo sapiens 156-161 33511940-2 2021 Interestingly, there is emerging evidence that the sulfonamide-type COX-2 selective inhibitors (coxibs) demonstrate inhibitory action against the cancer-related hCA isoforms, confirmed by X-ray crystal structures for celecoxib and valdecoxib complexes with the hCA active site. Sulfonamides 51-62 HCA1 Homo sapiens 161-164 33038795-9 2021 Furthermore, molecular modelling studies were applied to get a deep focus about the feasible affinities and binding interactions for target coumarin-sulfonamides 4, 5, 13 and 14 with the active site for CA II, IX and XII isoforms. Sulfonamides 149-161 carbonic anhydrase 2 Homo sapiens 203-208 33254069-7 2021 We have also described a successful example of bioisosteric replacement of the amide bond for a sulfonamide one [7e 6b], where we observed an increase in affinity and selectivity for CatB while lowering the compound lipophilicity (ilogP). Sulfonamides 96-107 cathepsin B Homo sapiens 185-189 33488256-6 2020 Secondary sulfonamides showed promising enzyme inhibitory effects on AChE while primary sulfonamide derivative was generally effective on hCA I and hCA II isoenzymes. Sulfonamides 10-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 33357183-4 2021 OBJECTIVES: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors. Sulfonamides 51-63 Janus kinase 1 Homo sapiens 26-30 33357183-4 2021 OBJECTIVES: To design new JAK1 inhibitors based on sulfonamides-triazine conjugates capable of binding interactions comparable to observed interactions anchoring potent crystallographic JAK1 inhibitors. Sulfonamides 51-63 Janus kinase 1 Homo sapiens 186-190 33357183-5 2021 METHODS: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors. Sulfonamides 153-164 Janus kinase 1 Homo sapiens 92-96 33357183-5 2021 METHODS: The crystallographic structures of 4 diverse nanomolar inhibitors complexed within JAK1 were used to guide the synthesis of new diaminotriazine-sulfonamide-based JAK1 inhibitors. Sulfonamides 153-164 Janus kinase 1 Homo sapiens 171-175 33488256-6 2020 Secondary sulfonamides showed promising enzyme inhibitory effects on AChE while primary sulfonamide derivative was generally effective on hCA I and hCA II isoenzymes. Sulfonamides 10-21 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 33137555-0 2020 Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates. Sulfonamides 19-30 prostaglandin-endoperoxide synthase 2 Homo sapiens 84-89 32946182-0 2020 Sulfonamide Inhibitors of ss-Catenin Signaling with Different Output on c-MYC as Anticancer Agents. Sulfonamides 0-11 MYC proto-oncogene, bHLH transcription factor Homo sapiens 72-77 33074119-1 2020 Herein, we report the synthesis of novel 2-substituted styrylquinazolines conjugated with aniline or sulfonamide moieties, anticipated to act as potent anticancer therapeutic agents through preferential EGFR inhibition. Sulfonamides 101-112 epidermal growth factor receptor Homo sapiens 203-207 33171408-3 2020 The docking studies suggest that 17 tightly binds to the Zn(II) of VIM-2 and CphA by the oxygen atoms of sulfonamide group, but coordinates with the Zn(II) of L1 through the oxygen atoms of hydroxamic acid group. Sulfonamides 105-116 vimentin 2, pseudogene Homo sapiens 67-72 33137555-2 2020 In this work, a novel series of sulfonamide-containing aminophosphonate derivatives (A1-A25) were developed as selective COX-2 inhibitors and anti-cancer candidates. Sulfonamides 32-43 immunoglobulin kappa variable 1-22 (pseudogene) Homo sapiens 88-91 33137555-2 2020 In this work, a novel series of sulfonamide-containing aminophosphonate derivatives (A1-A25) were developed as selective COX-2 inhibitors and anti-cancer candidates. Sulfonamides 32-43 prostaglandin-endoperoxide synthase 2 Homo sapiens 121-126 32401067-5 2020 The new sulphonamides showed low to moderate inhibition against hCAs, AChE, BChE, and tyrosinase enzymes. Sulfonamides 8-21 BCAR1 scaffold protein, Cas family member Homo sapiens 64-68 32866756-3 2020 We reported here the first identification of a series of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 inhibitors. Sulfonamides 107-118 kelch-like ECH-associated protein 1 Mus musculus 141-146 32866756-3 2020 We reported here the first identification of a series of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 inhibitors. Sulfonamides 107-118 nuclear factor, erythroid derived 2, like 2 Mus musculus 147-151 31813300-0 2020 Novel sulphonamides incorporating triazene moieties show powerful carbonic anhydrase I and II inhibitory properties. Sulfonamides 6-19 carbonic anhydrase 1 Homo sapiens 66-86 31813300-4 2020 The 4-fluoro substituted derivative might be considered as an interesting lead due to its effective inhibitory action against both hCA I and hCA II (KIs of 21 nM), a profile rarely seen among other sulphonamide CA inhibitors, making it of interest in systems where the activity of the two cytosolic isoforms is dysregulated. Sulfonamides 198-210 cytochrome P450 family 24 subfamily A member 1 Homo sapiens 131-147 31914827-0 2020 Synthesis and human carbonic anhydrase I, II, VA, and XII inhibition with novel amino acid-sulphonamide conjugates. Sulfonamides 91-103 carbonic anhydrase 1 Homo sapiens 20-40 31914827-5 2020 Some of these sulphonamides were also found to be effective inhibitors of hCA I, hCA VA, and hCA XII, with activity from the low to high nanomolar range. Sulfonamides 14-27 carbonic anhydrase 1 Homo sapiens 74-79 31914827-5 2020 Some of these sulphonamides were also found to be effective inhibitors of hCA I, hCA VA, and hCA XII, with activity from the low to high nanomolar range. Sulfonamides 14-27 carbonic anhydrase 12 Homo sapiens 93-100 31899985-0 2020 Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile. Sulfonamides 0-13 acetylcholinesterase (Cartwright blood group) Homo sapiens 79-99 32401067-5 2020 The new sulphonamides showed low to moderate inhibition against hCAs, AChE, BChE, and tyrosinase enzymes. Sulfonamides 8-21 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 31899985-0 2020 Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile. Sulfonamides 0-13 butyrylcholinesterase Homo sapiens 101-122 32401067-5 2020 The new sulphonamides showed low to moderate inhibition against hCAs, AChE, BChE, and tyrosinase enzymes. Sulfonamides 8-21 butyrylcholinesterase Homo sapiens 76-80 32401067-5 2020 The new sulphonamides showed low to moderate inhibition against hCAs, AChE, BChE, and tyrosinase enzymes. Sulfonamides 8-21 tyrosinase Homo sapiens 86-96 31899985-0 2020 Sulphonamides incorporating 1,3,5-triazine structural motifs show antioxidant, acetylcholinesterase, butyrylcholinesterase, and tyrosinase inhibitory profile. Sulfonamides 0-13 tyrosinase Homo sapiens 128-138 32156166-0 2020 Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells. Sulfonamides 15-26 matrix metallopeptidase 3 Homo sapiens 47-51 32466694-0 2020 Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo. Sulfonamides 23-36 indoleamine 2,3-dioxygenase 1 Homo sapiens 40-44 32156166-4 2020 Using the ilomastat Leu-Trp backbone, we have synthesised novel sulphonamides and monitored the performance of these compounds in conditioned media expressing MMP3. Sulfonamides 64-77 matrix metallopeptidase 3 Homo sapiens 159-163 32602377-1 2020 Many studies have been conducted on the selective inhibition of human monoamine oxidase B (hMAO-B) enzyme using benzylamine-sulphonamide derivatives. Sulfonamides 124-136 monoamine oxidase B Homo sapiens 70-89 32466694-2 2020 Herein, a variety of secondary sulphonamides were synthesised and evaluated in the HeLa cell-based IDO1/kynurenine assay, leading to the identification of new IDO1 inhibitors. Sulfonamides 31-44 indoleamine 2,3-dioxygenase 1 Homo sapiens 99-103 32602377-1 2020 Many studies have been conducted on the selective inhibition of human monoamine oxidase B (hMAO-B) enzyme using benzylamine-sulphonamide derivatives. Sulfonamides 124-136 monoamine oxidase B Homo sapiens 91-97 32466694-2 2020 Herein, a variety of secondary sulphonamides were synthesised and evaluated in the HeLa cell-based IDO1/kynurenine assay, leading to the identification of new IDO1 inhibitors. Sulfonamides 31-44 indoleamine 2,3-dioxygenase 1 Homo sapiens 159-163 32668994-5 2020 Additionally, the high potency of the pyrazole derivatives bearing sulphonamide against DHFR was confirmed with molecular docking and might be used as an optimum lead for further modification. Sulfonamides 67-79 dihydrofolate reductase Homo sapiens 88-92 32748253-0 2020 Evaluation of some thiophene-based sulfonamides as potent inhibitors of carbonic anhydrase I and II isoenzymes isolated from human erythrocytes by kinetic and molecular modelling studies. Sulfonamides 35-47 carbonic anhydrase 1 Homo sapiens 72-92 33039597-9 2020 The strain was identified as S. Typhimuirium ST19 harboring a 265.5 kbp pN1566-2 plasmid carryingthe genes encoding for resistance against colistin (mcr-9.1), aminoglycoside (aadA1), tetracycline (tet(C)), and sulfonamide (sul1). Sulfonamides 210-221 cyclin dependent kinase 2 associated protein 1 Homo sapiens 45-49 32748253-7 2020 RESULTS: Thiophene-based sulfonamides showed IC50 values of in the range of 69 nM to 70 microM against hCA-I, 23.4 nM to 1.405 microM against hCA-II. Sulfonamides 25-37 carbonic anhydrase 1 Homo sapiens 103-108 33184734-6 2021 Aminoglycoside resistance genes strA and strB, sulfonamide resistance gene sul1, and multidrug resistance gene qacDelta1-01 were the predominant ARGs. Sulfonamides 47-58 serpin family A member 2 (gene/pseudogene) Homo sapiens 145-149 32711315-4 2020 The results obtained showed that sulfonamides have a low retention in soils, with average adsorption percentages of 40% for SDZ, 44% for SMT and 54% for SCP, and with desorption percentages up to 36% for SDZ and SCP and up to 29% for SMT. Sulfonamides 33-45 urocortin 3 Homo sapiens 153-156 32711315-4 2020 The results obtained showed that sulfonamides have a low retention in soils, with average adsorption percentages of 40% for SDZ, 44% for SMT and 54% for SCP, and with desorption percentages up to 36% for SDZ and SCP and up to 29% for SMT. Sulfonamides 33-45 urocortin 3 Homo sapiens 212-215 32711315-6 2020 In addition, the hydrophobicity of sulfonamides also had an influence, as higher hydrophobicity resulted in higher affinity for soils, showing the affinity sequences: SDZ ~ SMT = 0.9938) and detection limits (0.02-0.04 ng mL-1) of sulfonamides were obtained. Sulfonamides 105-117 L1 cell adhesion molecule Mus musculus 96-100 34246058-3 2021 The prepared magnetic SnS2 composites were used for the enrichment of sulfonamide antibiotics (SAs), and various experimental parameters affecting the extraction efficiency were investigated. Sulfonamides 70-81 sodium voltage-gated channel alpha subunit 11 Homo sapiens 22-26 34481530-0 2021 Inhibition of carbonic anhydrase II by sulfonamide derivatives. Sulfonamides 39-50 carbonic anhydrase 2 Homo sapiens 14-35 34481530-1 2021 A series of sulfonamide derivatives were synthesized, and the enzyme inhibitory activity of the synthesized compounds on carbonic anhydrase II was evaluated. Sulfonamides 12-23 carbonic anhydrase 2 Homo sapiens 121-142 34325101-5 2021 The ARG composition was differently impacted by rapid urbanization and dam construction, which urbanization could promote ARGs resistant to sulfonamide and tetracycline, whereas dam construction could elevate the resistance to chloramphenicol and aminoglycoside. Sulfonamides 140-151 serpin family A member 2 (gene/pseudogene) Homo sapiens 122-126 34428264-6 2021 The E. coli ESBL isolates not only showed resistance to third generation cephalosporins but also to antibiotics from other groups, such as fluoroquinolones, aminoglycosides and sulfonamides. Sulfonamides 177-189 EsbL Escherichia coli 12-16 34445506-6 2021 CA IX activity as well as CA IX and CA XII protein levels were reduced by the betulin sulfonamides. Sulfonamides 86-98 carbonic anhydrase 9 Homo sapiens 0-5 34445506-6 2021 CA IX activity as well as CA IX and CA XII protein levels were reduced by the betulin sulfonamides. Sulfonamides 86-98 carbonic anhydrase 9 Homo sapiens 26-31 34445506-6 2021 CA IX activity as well as CA IX and CA XII protein levels were reduced by the betulin sulfonamides. Sulfonamides 86-98 carbonic anhydrase 12 Homo sapiens 36-42 34251523-2 2021 The MLR-3 method was trained with 82 molecules including drug-like sulfonamides and small organic molecules, which resembled the main functional groups present in the challenge dataset. Sulfonamides 67-79 CD69 molecule Homo sapiens 4-9 34389703-2 2021 Moreover, since RBM39 was identified as a target of sulfonamides, it has played a key role in the emerging field of molecule drug development. Sulfonamides 52-64 RNA binding motif protein 39 Homo sapiens 16-21 34251523-4 2021 Overall, the results support the appropriateness of multiple linear regression approach MLR-3 for computing the n-octanol/water partition coefficient in sulfonamide-bearing compounds. Sulfonamides 153-164 CD69 molecule Homo sapiens 88-93 35618035-1 2022 A simple and time-saving colorimetric method was developed to quantify sulfonamides (SAAs) in milk via inhibition of the human carbonic anhydrase II (hCAII)-like activity of ZIF-8 that can hydrolyze p-nitrophenyl acetate (pNPA) to p-nitrophenol (pNP), following the color change from yellow to colorless. Sulfonamides 71-83 carbonic anhydrase 2 Homo sapiens 127-148 35489270-0 2022 Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation. Sulfonamides 65-76 matrix metallopeptidase 2 Homo sapiens 32-37 35489270-0 2022 Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation. Sulfonamides 65-76 carbonic anhydrase 2 Homo sapiens 39-44 35489270-0 2022 Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation. Sulfonamides 65-76 kinase insert domain receptor Homo sapiens 49-56 35489270-8 2022 Herein, we report concomitant inhibition of MMP-2, CA II, and VEGFR-2 via rationally designed 1,2,3- and 1,2,4-triazole hybrids bearing various sulfonamide appendages following pharmacophore hybridization strategy. Sulfonamides 144-155 matrix metallopeptidase 2 Homo sapiens 44-49 35489270-8 2022 Herein, we report concomitant inhibition of MMP-2, CA II, and VEGFR-2 via rationally designed 1,2,3- and 1,2,4-triazole hybrids bearing various sulfonamide appendages following pharmacophore hybridization strategy. Sulfonamides 144-155 carbonic anhydrase 2 Homo sapiens 51-56 35489270-8 2022 Herein, we report concomitant inhibition of MMP-2, CA II, and VEGFR-2 via rationally designed 1,2,3- and 1,2,4-triazole hybrids bearing various sulfonamide appendages following pharmacophore hybridization strategy. Sulfonamides 144-155 kinase insert domain receptor Homo sapiens 62-69 35616541-4 2022 EXPERT OPINION: The available 3D crystal structures of hCA IX, XII as well as the off target isoforms hCA I and II, afforded structure-based drug design opportunities, which led to the development of various isoform-selective small molecule inhibitors belonging to diverse classes (sulfonamides, sulfamates, benzoxaboroles, selenols, coumarins, sulfocoumarins and isocoumarins). Sulfonamides 282-294 carbonic anhydrase 9 Homo sapiens 55-61 35616541-4 2022 EXPERT OPINION: The available 3D crystal structures of hCA IX, XII as well as the off target isoforms hCA I and II, afforded structure-based drug design opportunities, which led to the development of various isoform-selective small molecule inhibitors belonging to diverse classes (sulfonamides, sulfamates, benzoxaboroles, selenols, coumarins, sulfocoumarins and isocoumarins). Sulfonamides 282-294 HCA1 Homo sapiens 102-105 35461861-3 2022 To this end, we immobilized poly sulfonamide-thiazole (PST), a new group of sulfonamides, on the surface of layered double hydroxides/chitosan (LDH@CS). Sulfonamides 76-88 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 Homo sapiens 55-58 35466450-9 2022 Furthermore, we revealed that PL killed T24 cisplatin-resistant cells by triggering necroptosis, because cell death could be rescued by the mixed lineage kinase domain-like (MLKL) protein inhibitor necrotic sulfonamide or MLKL siRNA, but could not be suppressed by the apoptosis inhibitor z-VAD. Sulfonamides 207-218 mixed lineage kinase domain like pseudokinase Homo sapiens 140-172 35466450-9 2022 Furthermore, we revealed that PL killed T24 cisplatin-resistant cells by triggering necroptosis, because cell death could be rescued by the mixed lineage kinase domain-like (MLKL) protein inhibitor necrotic sulfonamide or MLKL siRNA, but could not be suppressed by the apoptosis inhibitor z-VAD. Sulfonamides 207-218 mixed lineage kinase domain like pseudokinase Homo sapiens 174-178 34358123-0 2021 Synthesis and Human Carbonic Anhydrase I, II, IX, and XII Inhibition Studies of Sulphonamides Incorporating Mono-, Bi- and Tricyclic Imide Moieties. Sulfonamides 80-93 carbonic anhydrase 1 Homo sapiens 20-40 34358123-4 2021 The physiologically dominant hCA II was significantly inhibited by most of the sulphonamide with the Kis ranging between 2.4 and 4515 nM. Sulfonamides 79-91 carbonic anhydrase 2 Homo sapiens 29-35 34358123-5 2021 hCA IX and hCA XII were inhibited by these sulphonamides in the range of 9.7 to 7766 nM and 14 to 316 nM, respectively. Sulfonamides 43-56 carbonic anhydrase 12 Homo sapiens 11-18 34173883-4 2021 In addition, in silico experiments have shown that the sulfonamide chalcone fits well in the ligand-binding site of EGFR with seven mu-alkyl binding energy interactions on the ligand-binding site. Sulfonamides 55-66 epidermal growth factor receptor Homo sapiens 116-120 34173883-5 2021 Finally, the kinetic stability and the pharmacophoric analysis for EGFR indicated the necessary spatial characteristics for potential activity of sulfonamide chalcone as an antagonist. Sulfonamides 146-157 epidermal growth factor receptor Homo sapiens 67-71 34080416-0 2021 Accurate Quantification of Sulfonamide Metabolites in Goat Meat: A New Strategy for Minimizing Interaction between Sheep Serum Albumin and Sulfonamide Metabolites. Sulfonamides 27-38 albumin Homo sapiens 127-134 34080416-0 2021 Accurate Quantification of Sulfonamide Metabolites in Goat Meat: A New Strategy for Minimizing Interaction between Sheep Serum Albumin and Sulfonamide Metabolites. Sulfonamides 139-150 albumin Homo sapiens 127-134 34080416-3 2021 Noncovalent interactions including van der Waals force, hydrogen bonding, and hydrophobic effect were determined to be staple interactions between the sulfonamide metabolites and sheep serum albumin by fluorescence spectroscopy and molecular docking technology, and an 80% acetonitrile-water solution/(NH4)2SO4 was used as ATPS in order to release combined sulfonamide metabolites and minimize the influence of sheep serum albumin. Sulfonamides 151-162 albumin Homo sapiens 185-198 34198834-5 2021 Sulphonamide CAIX inhibitor E showed the lowest IC50 and the highest selectivity index in CAIX-positive HeLa cells. Sulfonamides 0-12 carbonic anhydrase 9 Homo sapiens 13-17 34198834-5 2021 Sulphonamide CAIX inhibitor E showed the lowest IC50 and the highest selectivity index in CAIX-positive HeLa cells. Sulfonamides 0-12 carbonic anhydrase 9 Homo sapiens 90-94 35618035-1 2022 A simple and time-saving colorimetric method was developed to quantify sulfonamides (SAAs) in milk via inhibition of the human carbonic anhydrase II (hCAII)-like activity of ZIF-8 that can hydrolyze p-nitrophenyl acetate (pNPA) to p-nitrophenol (pNP), following the color change from yellow to colorless. Sulfonamides 71-83 carbonic anhydrase 2 Homo sapiens 150-155 35635948-0 2022 Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies. Sulfonamides 15-26 NLR family pyrin domain containing 3 Homo sapiens 33-38 35441519-1 2022 A convenient "green" stereoretentive approach to sp3-enriched secondary sulfonamides bearing an asymmetric center at the alpha position to the sulfur atom is described. Sulfonamides 72-84 Sp3 transcription factor Homo sapiens 49-52 35367710-0 2022 Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells. Sulfonamides 47-59 exportin 1 Rattus norvegicus 74-78 35149265-8 2022 Docking studies suggested that the endocyclic nitrogen of the quinoline ring, and exocyclic nitrogen of the sulfonamide functional group are coordinate with Zn(II) ion at active sites of NDM-1. Sulfonamides 108-119 Beta-lactamase Escherichia coli 187-192 35484599-1 2022 Saccharin is a cyclic secondary sulfonamide, which is a selective inhibitor of the tumor-associated carbonic anhydrase (CA; EC 4.2.1.1) enzymes CA IX and CA XII compared to many primary sulfonamides. Sulfonamides 32-43 carbonic anhydrase 12 Homo sapiens 154-160 35090939-0 2022 Identification of sulfonamide based butyrylcholinesterase inhibitors through scaffold hopping approach. Sulfonamides 18-29 butyrylcholinesterase Homo sapiens 36-57 35247094-1 2022 Two ternary copper(II) complexes with 2,2"-biquinoline (BQ) and with sulfonamides: sulfamethazine (SMT) or sulfaquinoxaline (SDQ) whose formulae are Cu(SMT)(BQ)Cl and Cu(SDQ)(BQ)Cl CH3OH, in what follows SMTCu and SDQCu, respectively, induced oxidative stress by increasing ROS level from 1.0 muM and the reduction potential of the couple GSSG/GSH2. Sulfonamides 69-81 GS homeobox 2 Homo sapiens 344-348 35123163-2 2022 We herein present the design, chemical synthesis, cellular imaging and biological assessment of a novel tumor-sensitive BRD4 ligand (compound 4) by introducing anticancer BRD4 inhibitor into naphthalimide moiety (fluorescent reporter) via a sulfonamide unit as glutathione (GSH)-specific cleavable linker. Sulfonamides 241-252 bromodomain containing 4 Homo sapiens 120-124 35123163-2 2022 We herein present the design, chemical synthesis, cellular imaging and biological assessment of a novel tumor-sensitive BRD4 ligand (compound 4) by introducing anticancer BRD4 inhibitor into naphthalimide moiety (fluorescent reporter) via a sulfonamide unit as glutathione (GSH)-specific cleavable linker. Sulfonamides 241-252 bromodomain containing 4 Homo sapiens 171-175 35123163-3 2022 Upon reaction with abundant intramolecular GSH in cancer cells or free GSH in aqueous solution (pH = 7.4), sulfonamide cleavage of 4 occurs, leading to the release of BRD4 inhibitor and concomitant fluorescence-on. Sulfonamides 107-118 bromodomain containing 4 Homo sapiens 167-171 35187312-2 2022 Here, we report the binding of well-known antibiotic sulfonamide drugs (sulfamethazine, SMZ; and sulfadiazine, SDZ) with heme protein myoglobin (Mb) using spectroscopic, calorimetric, zeta potential, and computational methods. Sulfonamides 53-64 myoglobin Homo sapiens 134-143 35187312-11 2022 Thus, the present study explores the potential binding characteristics of two sulfonamide drugs (with different substitutions) with myoglobin, correlating the structural and energetic aspects. Sulfonamides 78-89 myoglobin Homo sapiens 132-141 35174139-0 2022 Fluorescent Ligand-Based Discovery of Small-Molecule Sulfonamide Agonists for GPR120. Sulfonamides 53-64 free fatty acid receptor 4 Mus musculus 78-84